Journal
CELL
Volume 182, Issue 5, Pages 1295-+Publisher
CELL PRESS
DOI: 10.1016/j.cell.2020.08.012
Keywords
-
Categories
Funding
- NIAID/NIH [R01AI141707, R01AI12893, HHSN272201700059C, F30AI149928, T32AI083203]
- Pew Biomedical Scholars Award
- Burroughs Wellcome Investigators in the Pathogenesis of Infectious Diseases
- NIGMS/NIH [R01GM120553]
- Bill & Melinda Gates Foundation [OPP1156262]
- Fast Grants
- Damon Runyon Cancer Research Foundation [DRG-2381-19]
Ask authors/readers for more resources
The receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein mediates viral attachment to ACE2 receptor and is a major determinant of host range and a dominant target of neutralizing antibodies. Here, we experimentally measure how all amino acid mutations to the RBD affect expression of folded protein and its affinity for ACE2. Most mutations are deleterious for RBD expression and ACE2 binding, and we identify constrained regions on the RBD's surface that may be desirable targets for vaccines and antibody-based therapeutics. But a substantial number of mutations are well tolerated or even enhance ACE2 binding, including at ACE2 interface residues that vary across SARS-related coronaviruses. However, we find no evidence that these ACE2-affinity-enhancing mutations have been selected in current SARS-CoV-2 pandemic isolates. We present an interactive visualization and open analysis pipeline to facilitate use of our dataset for vaccine design and functional annotation of mutations observed during viral surveillance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available